These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8430064)

  • 1. Mean residence time of oral drugs undergoing first-pass and linear reversible metabolism.
    Cheng H; Jusko WJ
    Pharm Res; 1993 Jan; 10(1):8-13. PubMed ID: 8430064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ratio of first to zeroth moments of the plasma profile of an oral drug undergoing first-pass and linear reversible metabolism.
    Cheng H
    Biopharm Drug Dispos; 1995 Dec; 16(9):791-6. PubMed ID: 8580402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A method for calculating the mean absorption time of drugs undergoing reversible and first-pass metabolism.
    Cheng H; Shum L
    Biopharm Drug Dispos; 1993 Jan; 14(1):71-9. PubMed ID: 8427946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mean residence time of drugs administered non-instantaneously and undergoing linear tissue distribution and reversible metabolism and linear or non-linear elimination from the central compartment.
    Cheng H
    Biopharm Drug Dispos; 1995 May; 16(4):259-67. PubMed ID: 7548775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of first-pass metabolism on metabolite mean residence time determination after oral administration of parent drug.
    Chan KK; Gibaldi M
    Pharm Res; 1990 Jan; 7(1):59-63. PubMed ID: 2300537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mean residence times and distribution volumes for drugs undergoing linear reversible metabolism and tissue distribution and linear or nonlinear elimination from the central compartments.
    Cheng HY; Jusko WJ
    Pharm Res; 1991 Apr; 8(4):508-11. PubMed ID: 1871048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A general model of metabolite kinetics following intravenous and oral administration of the parent drug.
    Weiss M
    Biopharm Drug Dispos; 1988; 9(2):159-76. PubMed ID: 3370305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Constant-rate intravenous infusion methods for estimating steady-state volumes of distribution and mean residence times in the body for drugs undergoing reversible metabolism.
    Cheng H; Jusko WJ
    Pharm Res; 1990 Jun; 7(6):628-32. PubMed ID: 2367330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of mean residence-time concepts to pharmacokinetic systems with noninstantaneous input and nonlinear elimination.
    Cheng HY; Jusko WJ
    Pharm Res; 1989 Jan; 6(1):4-12. PubMed ID: 2717515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The application of sample pooling methods for determining AUC, AUMC and mean residence times in pharmacokinetic studies.
    Cheung BW; Cartier LL; Russlie HQ; Sawchuk RJ
    Fundam Clin Pharmacol; 2005 Jun; 19(3):347-54. PubMed ID: 15910659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary, secondary, and tertiary metabolite kinetics.
    St-Pierre MV; Xu X; Pang KS
    J Pharmacokinet Biopharm; 1988 Oct; 16(5):493-527. PubMed ID: 3199316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of sequential metabolism. Contribution of parallel, primary metabolic pathways to the formation of a common, secondary metabolite.
    Pang KS
    Drug Metab Dispos; 1995 Feb; 23(2):166-77. PubMed ID: 7736907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of metabolites in bioequivalency assessment. II. Drugs with linear pharmacokinetics and first-pass effect.
    Chen ML; Jackson AJ
    Pharm Res; 1995 May; 12(5):700-8. PubMed ID: 7479556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mean interconversion times and distribution rate parameters for drugs undergoing reversible metabolism.
    Cheng HY; Jusko WJ
    Pharm Res; 1990 Oct; 7(10):1003-10. PubMed ID: 2281028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I).
    Fernández-Teruel C; Nalda Molina R; González-Alvarez I; Navarro-Fontestad C; García-Arieta A; Casabó VG; Bermejo M
    Eur J Pharm Sci; 2009 Jan; 36(1):137-46. PubMed ID: 19028574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of bioavailability and systemically available fractions of drugs undergoing reversible metabolism: application to 4-amino-5-chloro-2-[2-(methylsulfinyl)ethoxy]-N-[2- (diethylamino)ethyl]benzamide and its sulfide and sulfone metabolites in rats.
    Kuo BS; Poole JC; Hwang KK; Cheng H
    J Pharm Sci; 1994 Mar; 83(3):386-90. PubMed ID: 8207687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mean time and first-pass metabolism.
    Brockmeier D; Ostrowski J
    Eur J Clin Pharmacol; 1985; 29(1):45-8. PubMed ID: 3840437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-compartmental analysis of pharmacokinetic data after multiple intravenous and oral administration.
    Rohatagi S; Kan S; Derendorf H
    Pharmazie; 1997 Jul; 52(7):529-32. PubMed ID: 9266589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between drug input and mean residence time in the body.
    Bialer M; Look ZM; Silber BM; Yacobi A
    Biopharm Drug Dispos; 1986; 7(6):577-83. PubMed ID: 3828487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-pass elimination. Basic concepts and clinical consequences.
    Pond SM; Tozer TN
    Clin Pharmacokinet; 1984; 9(1):1-25. PubMed ID: 6362950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.